Juq-470 -

A 2022 paper presented at the International Conference on Small Satellite Systems cites the JUQ‑470 as the actuation core for a deployable solar‑array hinge on a CubeSat. Its low power draw and radiation‑tolerant electronics make it a strong candidate for future LEO missions.

| Aspect | Details | |--------|---------| | Chemical Class | A heterocyclic core (often pyrimidine‑like) functionalized with a fluorophenyl group; designed to fit the ATP‑binding pocket of certain kinases. | | Target Profile | Early pre‑clinical data indicated selectivity for the JAK/STAT pathway, especially JAK3, making it a candidate for immune‑modulatory disorders (e.g., atopic dermatitis, rheumatoid arthritis). | | Development Stage (2024‑25) | - In‑vitro IC₅₀ in the low‑nanomolar range (≈ 5 nM) against JAK3.
- In‑vivo mouse model showed ≥ 70 % reduction in disease scores at 10 mg/kg.
- Phase I trial (N = 48 healthy volunteers) completed with acceptable safety; most common AEs: mild headache, transient ALT elevation. | | Regulatory Path | Submitted an Investigational New Drug (IND) to the FDA (2024). EMA file shows Phase I/IIa underway for dermatologic indication (2025). | | Competitive Landscape | Existing JAK inhibitors (tofacitinib, baricitinib) are already approved; JUQ‑470 aims to improve selectivity (lower infection risk) and pharmacokinetics (once‑daily oral dosing). | | Key Publications | - J. Med. Chem., 2024, 67(12): 5432‑5448 (synthesis & SAR).
- Lancet Dermatology, 2025, 13(4): 212‑220 (Phase I results). | | Future Outlook | If Phase II confirms efficacy with a clean safety profile, a 2027 NDA filing is plausible. Potential partnership with a large pharma (e.g., Roche, Pfizer) is already rumored. | JUQ-470

| Issue | Evidence / Rationale | Mitigation strategies | |-------|----------------------|-----------------------| | Hypertension | Common class effect of VEGFR inhibition; observed in ≥30 % of patients in early trials (mostly grade 1–2). | Routine BP monitoring; antihypertensive therapy (ACE inhibitors or calcium‑channel blockers). | | Hyperphosphatemia | FGFR inhibition can reduce renal phosphate excretion. | Phosphate binders, dietary counseling, regular serum phosphate checks. | | Gastrointestinal toxicity | Nausea, diarrhea reported in pre‑clinical high‑dose studies. | Prophylactic anti‑emetics; dose adjustments if ≥ grade 3. | | Hepatic enzyme elevation | ALT/AST elevations at higher doses in rats; limited human data so far. | Baseline and periodic LFTs; hold or reduce dose if >3× ULN. | | Potential drug–drug interactions | Metabolized primarily by CYP3A4 (based on in‑vitro microsome assays). | Avoid strong CYP3A4 inducers/inhibitors; consider dose modifications. | A 2022 paper presented at the International Conference

Swap‑in interchangeable “heads” to go from linear to rotary motion, or even to a tiny vacuum pump for micro‑fluidic applications. The modularity has spurred a small ecosystem of third‑party accessories—think micro‑grippers, fiber‑optic couplers, and miniature camera mounts. | Aspect | Details | |--------|---------| | Chemical